X0609 4 2026-05-18 0001662774 Quince Therapeutics, Inc. QNCX 0001346566 Roberts Brigette false C/O QUINCE THERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 273 SOUTH SAN FRANCISCO CA 94080 true true false false Chief Corp. Affairs Officer 0 Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 34675 A 2031-03-01 Common Stock 34675 34675 D Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 228855 A 2032-04-07 Common Stock 228855 228855 D Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 124830 A 2032-09-05 Common Stock 124830 124830 D Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 69350 A 2033-07-30 Common Stock 69350 69350 D Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 362092 A 2034-03-14 Common Stock 362092 362092 D Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 133615 A 2034-08-12 Common Stock 133615 133615 D Employee Stock Option (Right to Buy) 0.09 2026-05-18 4 A 0 2070107 A 2036-03-15 Common Stock 2070107 2070107 D Employee Stock Option (Right to Buy) 0.84 2026-05-18 4 A 0 6837319 A 2036-05-11 Common Stock 6837319 6837319 D Employee Stock Option (Right to Buy) 0.84 2026-05-18 4 A 0 6837319 A 2036-05-11 Common Stock 6837319 6837319 D Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. Immediately exercisable. Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date. /s/ Brendan Hannah, Attorney-in-Fact 2026-06-11